How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
40
TRVI Quote, Financials, Valuation and Earnings
Last price:
$10.69
Seasonality move
:
91.5%
Day range:
$10.24 - $11.10
52-week range:
$3.77 - $14.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.10x
Volume:
1.9M
Avg. volume:
1.6M
1-year change:
166.08%
Market cap:
$1.3B
Revenue:
--
EPS (TTM):
-$0.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TRVI
Trevi Therapeutics, Inc.
|
-- | -$0.10 | -- | -34.24% | $21.30 |
|
ABUS
Arbutus Biopharma Corp.
|
$599.1K | -$0.04 | -61.94% | -39.55% | $5.70 |
|
BMY
Bristol Myers Squibb Co.
|
$12.3B | $1.24 | -7.02% | 17.19% | $58.04 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.80 | 195.3% | 90.44% | $14.86 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TRVI
Trevi Therapeutics, Inc.
|
$10.51 | $21.30 | $1.3B | -- | $0.00 | 0% | -- |
|
ABUS
Arbutus Biopharma Corp.
|
$4.14 | $5.70 | $796.2M | -- | $0.00 | 0% | 54.20x |
|
BMY
Bristol Myers Squibb Co.
|
$54.62 | $58.04 | $111.2B | 18.44x | $0.63 | 4.56% | 2.32x |
|
CRMD
CorMedix, Inc.
|
$7.75 | $14.86 | $610.6M | 3.77x | $0.00 | 0% | 2.61x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$2.00 | $0.85 | $252.3M | 3.36x | $0.80 | 0% | 3.89x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TRVI
Trevi Therapeutics, Inc.
|
0.43% | -2.959 | 0.07% | 21.56x |
|
ABUS
Arbutus Biopharma Corp.
|
5.62% | -0.113 | 0.53% | 18.25x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.335 | 56.92% | 0.94x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TRVI
Trevi Therapeutics, Inc.
|
-$38K | -$13.9M | -35.21% | -35.48% | -- | -$10.9M |
|
ABUS
Arbutus Biopharma Corp.
|
$518K | -$8.3M | -44.8% | -47.63% | -1567.68% | -$5.8M |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Trevi Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TRVI or ABUS?
Arbutus Biopharma Corp. has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of -1463.52%. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat Arbutus Biopharma Corp.'s return on equity of -47.63%.
Company Gross Margin Earnings Per Share Invested Capital TRVITrevi Therapeutics, Inc.-- -$0.08 $190.6M ABUSArbutus Biopharma Corp.97.92% -$0.04 $82M -
What do Analysts Say About TRVI or ABUS?
Trevi Therapeutics, Inc. has a consensus price target of $21.30, signalling upside risk potential of 102.66%. On the other hand Arbutus Biopharma Corp. has an analysts' consensus of $5.70 which suggests that it could grow by 37.6%. Given that Trevi Therapeutics, Inc. has higher upside potential than Arbutus Biopharma Corp., analysts believe Trevi Therapeutics, Inc. is more attractive than Arbutus Biopharma Corp..
Company Buy Ratings Hold Ratings Sell Ratings TRVITrevi Therapeutics, Inc.9 0 0 ABUSArbutus Biopharma Corp.2 0 0 -
Is TRVI or ABUS More Risky?
Trevi Therapeutics, Inc. has a beta of 0.907, which suggesting that the stock is 9.324% less volatile than S&P 500. In comparison Arbutus Biopharma Corp. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.701%.
-
Which is a Better Dividend Stock TRVI or ABUS?
Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arbutus Biopharma Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. Arbutus Biopharma Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRVI or ABUS?
Trevi Therapeutics, Inc. quarterly revenues are --, which are smaller than Arbutus Biopharma Corp. quarterly revenues of $529K. Trevi Therapeutics, Inc.'s net income of -$11.8M is lower than Arbutus Biopharma Corp.'s net income of -$7.7M. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while Arbutus Biopharma Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus 54.20x for Arbutus Biopharma Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRVITrevi Therapeutics, Inc.-- -- -- -$11.8M ABUSArbutus Biopharma Corp.54.20x -- $529K -$7.7M
-
Which has Higher Returns TRVI or BMY?
Bristol Myers Squibb Co. has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of 17.96%. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital TRVITrevi Therapeutics, Inc.-- -$0.08 $190.6M BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About TRVI or BMY?
Trevi Therapeutics, Inc. has a consensus price target of $21.30, signalling upside risk potential of 102.66%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $58.04 which suggests that it could grow by 6.27%. Given that Trevi Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Trevi Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings TRVITrevi Therapeutics, Inc.9 0 0 BMYBristol Myers Squibb Co.5 17 1 -
Is TRVI or BMY More Risky?
Trevi Therapeutics, Inc. has a beta of 0.907, which suggesting that the stock is 9.324% less volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.215%.
-
Which is a Better Dividend Stock TRVI or BMY?
Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.56% to investors and pays a quarterly dividend of $0.63 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TRVI or BMY?
Trevi Therapeutics, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Trevi Therapeutics, Inc.'s net income of -$11.8M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRVITrevi Therapeutics, Inc.-- -- -- -$11.8M BMYBristol Myers Squibb Co.2.32x 18.44x $12.2B $2.2B
-
Which has Higher Returns TRVI or CRMD?
CorMedix, Inc. has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of 49.9%. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital TRVITrevi Therapeutics, Inc.-- -$0.08 $190.6M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About TRVI or CRMD?
Trevi Therapeutics, Inc. has a consensus price target of $21.30, signalling upside risk potential of 102.66%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 91.71%. Given that Trevi Therapeutics, Inc. has higher upside potential than CorMedix, Inc., analysts believe Trevi Therapeutics, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRVITrevi Therapeutics, Inc.9 0 0 CRMDCorMedix, Inc.4 0 0 -
Is TRVI or CRMD More Risky?
Trevi Therapeutics, Inc. has a beta of 0.907, which suggesting that the stock is 9.324% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock TRVI or CRMD?
Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRVI or CRMD?
Trevi Therapeutics, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Trevi Therapeutics, Inc.'s net income of -$11.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus 2.61x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRVITrevi Therapeutics, Inc.-- -- -- -$11.8M CRMDCorMedix, Inc.2.61x 3.77x $104.3M $108.6M
-
Which has Higher Returns TRVI or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of -255.85%. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital TRVITrevi Therapeutics, Inc.-- -$0.08 $190.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About TRVI or NBY?
Trevi Therapeutics, Inc. has a consensus price target of $21.30, signalling upside risk potential of 102.66%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -57.5%. Given that Trevi Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Trevi Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRVITrevi Therapeutics, Inc.9 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is TRVI or NBY More Risky?
Trevi Therapeutics, Inc. has a beta of 0.907, which suggesting that the stock is 9.324% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock TRVI or NBY?
Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRVI or NBY?
Trevi Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Trevi Therapeutics, Inc.'s net income of -$11.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus 3.89x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRVITrevi Therapeutics, Inc.-- -- -- -$11.8M NBYNovaBay Pharmaceuticals, Inc.3.89x 3.36x $521K -$1.3M
-
Which has Higher Returns TRVI or PTN?
Palatin Technologies has a net margin of -- compared to Trevi Therapeutics, Inc.'s net margin of --. Trevi Therapeutics, Inc.'s return on equity of -35.48% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TRVITrevi Therapeutics, Inc.-- -$0.08 $190.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About TRVI or PTN?
Trevi Therapeutics, Inc. has a consensus price target of $21.30, signalling upside risk potential of 102.66%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Trevi Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Trevi Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TRVITrevi Therapeutics, Inc.9 0 0 PTNPalatin Technologies0 0 0 -
Is TRVI or PTN More Risky?
Trevi Therapeutics, Inc. has a beta of 0.907, which suggesting that the stock is 9.324% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock TRVI or PTN?
Trevi Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Trevi Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TRVI or PTN?
Trevi Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Trevi Therapeutics, Inc.'s net income of -$11.8M is higher than Palatin Technologies's net income of --. Notably, Trevi Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Trevi Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TRVITrevi Therapeutics, Inc.-- -- -- -$11.8M PTNPalatin Technologies-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
